AbbVie's $70M Bet: New Drug & Stock Surge
Update: 2025-10-01
Description
AbbVie's stock skyrockets 5% after FDA submission for a breakthrough cancer drug and a $70M U.S. expansion, defying a downgrade and riding high on potential drug pricing deal optimism. Is this stability giant about to become a growth stock powerhouse?
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
